Schrodinger (SDGR) said Monday it plans to launch its predictive toxicology tool to customers in H2.

The computational tool is targeted to improve the properties of drug development candidates and lessen the risk of development failure related to binding off-target proteins, the company said.

The tool is in line with the plan of the US Food and Drug Administration to wind down animal testing requirement for monoclonal antibodies and other drugs, the company said.

"We believe our computational solutions will play a vital role in significantly reducing the use of animal models in preclinical development," Schrodinger CEO Ramy Farid said.

Price: 25.76, Change: +1.27, Percent Change: +5.19